[go: up one dir, main page]

WO2010149794A3 - Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane) - Google Patents

Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane) Download PDF

Info

Publication number
WO2010149794A3
WO2010149794A3 PCT/EP2010/059149 EP2010059149W WO2010149794A3 WO 2010149794 A3 WO2010149794 A3 WO 2010149794A3 EP 2010059149 W EP2010059149 W EP 2010059149W WO 2010149794 A3 WO2010149794 A3 WO 2010149794A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
allylamin
hydroxypropane
diallyl
diamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/059149
Other languages
French (fr)
Other versions
WO2010149794A2 (en
Inventor
Sergio Lloret Pérez
Laura Díaz Guasch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Combino Pharm SL
Original Assignee
Combino Pharm SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200930368A external-priority patent/ES2350999B1/en
Application filed by Combino Pharm SL filed Critical Combino Pharm SL
Publication of WO2010149794A2 publication Critical patent/WO2010149794A2/en
Publication of WO2010149794A3 publication Critical patent/WO2010149794A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

A solid, pharmaceutical composition for oral administration comprising from about 80% to about 94% by weight of sevelamer including the water of hydration and at least one pharmaceutically acceptable excipient.
PCT/EP2010/059149 2009-06-26 2010-06-28 Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane) Ceased WO2010149794A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ES200930368 2009-06-26
ES200930368A ES2350999B1 (en) 2009-06-26 2009-06-26 NEW PHARMACEUTICAL COMPOSITION UNDERSTANDING POLY HYDROCHLORIDE (ALILAMIN-CO-N, N'-DIALIL-1,3-DIAMINO-2-PROPANE HYDROXY).
PCT/EP2009/058122 WO2010149230A1 (en) 2009-06-26 2009-06-29 Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane) hydrochloride
EPPCT/EP2009/058122 2009-06-29
ARP20100102272 2010-06-25
ARP100102272A AR077244A1 (en) 2009-06-26 2010-06-25 PHARMACEUTICAL COMPOSITION THAT INCLUDES POLI (ALILAMIN-CO-N, N'-DIALIL-1,3-DIAMINO-2-HYDROXIPROPANE)

Publications (2)

Publication Number Publication Date
WO2010149794A2 WO2010149794A2 (en) 2010-12-29
WO2010149794A3 true WO2010149794A3 (en) 2011-06-16

Family

ID=43386953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/059149 Ceased WO2010149794A2 (en) 2009-06-26 2010-06-28 Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane)

Country Status (1)

Country Link
WO (1) WO2010149794A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159881A (en) * 2011-12-14 2013-06-19 上海亿法医药科技有限公司 Preparation method for sevelamer hydrochloride
CN103159880B (en) * 2011-12-14 2016-06-22 上海亿法医药科技有限公司 The preparation method of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545907A1 (en) * 2011-07-15 2013-01-16 Combino Pharm, S.L. Aqueous wet granulation process for cross-linked polyallylamine polymers
CN111773190A (en) * 2020-06-24 2020-10-16 北京瑞迪道森医药科技有限公司 Sevelamer carbonate tablet for improving safety of preparation and preparation method thereof
CN118924783B (en) * 2024-10-15 2025-05-16 湖州亚瑟制药有限公司 A preparation method for controlling hyperphosphatemia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028527A2 (en) * 1999-10-19 2001-04-26 Geltex Pharmaceuticals, Inc. Direct compression polymer tablet core
WO2007094779A1 (en) * 2006-02-14 2007-08-23 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
WO2008062437A2 (en) * 2006-09-01 2008-05-29 Usv Limited Process for the preparation of sevelamer hydrochloride and formulation thereof
WO2009034540A1 (en) * 2007-09-11 2009-03-19 Ranbaxy Laboratories Limited Pharmaceutical composition of sevelamer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW592727B (en) 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028527A2 (en) * 1999-10-19 2001-04-26 Geltex Pharmaceuticals, Inc. Direct compression polymer tablet core
WO2007094779A1 (en) * 2006-02-14 2007-08-23 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
WO2008062437A2 (en) * 2006-09-01 2008-05-29 Usv Limited Process for the preparation of sevelamer hydrochloride and formulation thereof
WO2009034540A1 (en) * 2007-09-11 2009-03-19 Ranbaxy Laboratories Limited Pharmaceutical composition of sevelamer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159881A (en) * 2011-12-14 2013-06-19 上海亿法医药科技有限公司 Preparation method for sevelamer hydrochloride
CN103159881B (en) * 2011-12-14 2016-04-27 上海亿法医药科技有限公司 The preparation method of sevelamer hydrochloride
CN103159880B (en) * 2011-12-14 2016-06-22 上海亿法医药科技有限公司 The preparation method of 2-Propen-1-amine polymer with(chloromethyl)oxirane carbonate

Also Published As

Publication number Publication date
WO2010149794A2 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
MX2012000369A (en) Tamper-resistant dosage form for oxidation-sensitive oploids.
WO2010146179A3 (en) Solid pharmaceutical composition comprising rivaroxaban
WO2010084115A3 (en) Antiviral agents
WO2008012622A3 (en) Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2008122965A3 (en) Pharmaceutical cyclosporin compositions
WO2007135527A3 (en) Benzimidazolyl compounds
WO2010092090A3 (en) Novel salts of sitagliptin
EP4538227A3 (en) Sodium thiosulfate-containing pharmaceutical compositions
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2008154083A3 (en) Compounds, compositions and methods for the treatment of synucleinopathies
IL214942A (en) N,n-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same and uses thereof in the preparation of medicaments
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
UA105766C2 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
WO2009081174A3 (en) Anti - retroviral combination
WO2012087255A3 (en) Pharmaceutical formulations comprising imatinib
JP2009537554A5 (en)
BRPI1009392A2 (en) "pharmaceutical formulation, and use of a pharmaceutically effective amount of a pharmaceutical formulation."
MX2013000474A (en) Novel arylamide derivatives having antiandrogenic properties.
EP2241310A3 (en) Modified release formulations of emoxypine
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
WO2010049449A3 (en) Novel salts of sunitinib
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010149794A3 (en) Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane)
WO2012020301A3 (en) Oral controlled release pharmaceutical compositions of blonanserin
EP2384746A3 (en) Dual release oral tablet compositions of dexlansoprazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10730415

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10730415

Country of ref document: EP

Kind code of ref document: A2